Mbodies Pilates Instructor Training Academy

  The 2023 American Society for Clinical Oncology (ASCO) annual clinical meeting in cancer research showcased groundbreaking advances in Breast Cancer treatment. Among the plethora of clinical trial updates, two stand out as game-changers. Firstly, CDK4/6 inhibitors are taking a prominent position in Breast Cancer therapy.  Cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) are enzymes important in cell division.  CDK4/6 inhibitors are drugs designed to interrupt the growth of cancer cells.  CDK4/6 inhibitors are used in combination with hormone therapy to treat some Breast Cancers.  These inhibitors block cancer cells' growth cycle, preventing cancer progression, and were initially developed as a treatment option for endocrine therapy-resistant Breast Cancer.  Palbociclib (Ibrance®) received American FDA approval in 2015, followed by ribociclib (Kisqali®) and abemaciclib (Verzenio®) in 2017 and in the UK NICE approved it in 2018.  Researchers presented trials with these inhibitors

The Pink Ribbon Breast Cancer Rehabilitation course will prepare Pilates Instructors to qualify and be certified as a Breast Cancer Exercise specialist. Overview of Breast Cancer in the UK   One in nine women will be diagnosed with Breast Cancer at some time in their life and according to the UK Office of National Statistics Breast Cancer is the most common form of cancer in England. More than 11,500 people will die of Breast Cancer every year.   Over 600,000 people who have been treated for Breast Cancer are currently living in the UK.    For many thousands of women who have survived Breast Cancer the disease will return, and the cycle of treatment and decision making will start all over again,  the return of the cancer may or may not be related to the first incidence. In 2010 there were approximately 50,000 new cases of Breast Cancer in women and 400 cases in men with the highest incidence in the 60 to 70-year-old age range.  Less than 20% of all Breast Cancer new diagnoses are in wo